Meanwhile, take a look at shares of Novo today falling to a four-year low this morning after results from its highly anticipated Alzheimer's drug trial failed to meet its main goal. The trial showed Novo's weight loss drug MGovi did not slow the progression of Alzheimer's. Joining us with some reaction today, city's head of US Pharma and biotech research Jeff Meum is with us.Jeff, thanks for the time. Good to see you again. >> Yeah, you too, Carl.Thank you for having me. >> I've seen the phrase longshot ass ...

Joining me now to discuss is Evan Seagerman. He's the head of healthcare research at Vimo Capital Markets. Evan, thank you so much for being here.It feels like over the course of the year when we've looked at sector specific recommendations. In the beginning, it was healthcare. Then that trade kind of went quiet for a while and perhaps maybe now it's seeing a resurgence.What do you think is behind it and can it continue. >> So, a few things. First of all, I think the recent deals you've seen with some pharm ...

A new study finding the use of weight loss drugs in kids has skyrocketed. Take a look at this. The study found that prescribing GLP1s for weight management in kids aged 8 to 17 increased 65% after the American Academy of Pediatrics issued guidelines recommending them 2 and a half years ago.Obviously, this was a recommendation by trusted pediatricians. But how young is too young for kids to go on these drugs. I mean, I think it's really a case-byase basis.The youngest in my practice is nine. But we look at o ...